Fresenius SE & Co KGaA (FRE) PT Set at €51.50 by UBS Group

UBS Group set a €51.50 ($59.88) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research report released on Friday, www.boersen-zeitung.de reports. The brokerage currently has a sell rating on the stock.

Other analysts have also recently issued reports about the company. Commerzbank set a €79.00 ($91.86) price objective on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Friday, August 24th. Barclays set a €80.00 ($93.02) price objective on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Friday, August 24th. Sanford C. Bernstein set a €83.00 ($96.51) price objective on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Thursday, August 9th. Morgan Stanley set a €77.00 ($89.53) price objective on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Monday, September 3rd. Finally, Warburg Research set a €80.00 ($93.02) price objective on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Friday, September 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of €68.69 ($79.88).

Fresenius SE & Co KGaA stock traded down €8.39 ($9.76) during mid-day trading on Friday, reaching €38.99 ($45.34). 12,548,201 shares of the company were exchanged. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($69.95) and a twelve month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: Stock Split

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply